A Study of DOX-SL in the Treatment of AIDS-Related Kaposi's Sarcoma

Inclusion Criteria Concurrent Medication: Allowed: * Prophylaxis for PCP, cryptococcal, and herpes infections, and antiretroviral therapy provided these doses have been stable for at least 1 month. * Maintenance therapy for tuberculosis, fungal, and herpes infections. * Therapy for new episodes of tuberculosis, fungal, and herpes infections except with potentially myelotoxic chemotherapy. * Foscarnet or ganciclovir for CMV infection. * Colony stimulating factors and erythropoietin. Patients must have: * Moderate to severe AIDS-related Kaposi's sarcoma. * Documented anti-HIV antibody. * No active opportunistic infection with mycobacteria, cytomegalovirus, toxoplasma, Pneumocystis carinii, or other microorganisms (if under treatment with myelotoxic drugs). NOTE: * Eligible KS patients include those who have discontinued therapy in the control arm of a DOX-SL KS study because of side effects or inadequate efficacy OR other KS patients for whom DOX-SL is believed to be indicated. Patients must not be eligible for other Liposome Technology protocols comparing DOX-SL with established therapies. Exclusion Criteria Co-existing Condition: Patients with the following symptoms or conditions are excluded: * Clinically significant cardiac disease. * Confusion or disorientation. Concurrent Medication: Excluded: * Other cytotoxic cancer chemotherapy. Patients with the following prior conditions are excluded: * Prior neoplasms treated with extensive chemotherapy that, in the investigator's opinion, has led to an irreversibly compromised marrow function. * History of idiosyncratic or allergic reaction to anthracyclines. * History of major psychiatric illness. Prior Medication: Excluded within the past 4 weeks: * Cytotoxic chemotherapy (other than in a qualifying Liposome Technology protocol). * Interferon treatment. Prior Treatment: Excluded within the past 3 weeks: * Radiation or electron beam therapy.